Effectiveness and retention of certolizumab pegol and JAK inhibitors in rheumatoid arthritis: a multicenter retrospective study stratified by rheumatoid factor status

Background

Patients with rheumatoid arthritis (RA) and high levels of Rheumatoid Factor (RF) often present with a higher inflammatory burden and may show a reduced response to JAK inhibitors (JAKi). However, previous studies have demonstrated that certolizumab pegol (CZP) provides comparable efficacy in patients regardless of RF level.